The firm's dual payload antibody-drug conjugate CLIO-8221 contains both a topoisomerase 1 inhibitor and an ATR inhibitor.

Ascletis Pharma has posted phase 2 data on its ultra-long-acting GLP-1 receptor analog, generating early evidence that the formulation may support quarterly dosing as a maintenance therapy. Eli ...

Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...

Diana is a News Writer from Peru. She graduated as a journalist in 2020 and has since gained experience in news, social media, and marketing. Previously, she worked as a tech and gaming news writer in ...

ARLINGTON, Va.--(BUSINESS WIRE)--Today, Venture Global, Inc. (NYSE: VG) is announcing a final investment decision (FID) and successful closing of an $8.6 billion project financing for the second phase ...

While players are largely leaving Season 2 due to a lack of content, the game has largely been giving players positive signals it’s on the right track. The previously released map in the season was ...

The recurring blackout at the University College Hospital (UCH), Ibadan, has once again drawn public attention to the fragility of critical infrastructure in Nigeria’s health sector, with patients, ...